Alkermes says API demand is safe; Oxygen taps PPD for Phase IIb;

> Alkermes ($ALKS) says the CMO demand for highly potent APIs can withstand Big Pharma in-sourcing. Article

> CROs need to diversify to survive, according to Catalyst Corporate Finance, as the market favors operations that can fill as many R&D roles as possible. Story

> Outsourcing-Pharma held a reader poll to determine just what "CRO" stands for in the minds of industry players. More

> Oxygen Biotherapeutics ($OXBT) has tapped PPD to conduct a Phase IIb clinical trial for Oxycyte, a brain injury treatment. News

> Icon ($ICLR) has reached out to Wingspan Technology for its cloud-based clinical trial system. Item

> CRO Onyx Scientific has named Dan Brisard its business development director. Release

Suggested Articles

Dubbed “Project Nightingale,” the efforts were announced amid concerns and federal inquiries into the data’s safekeeping and patient consent for use.

Independent site management organization Panthera Biopartners has kick-started its first clinical trial in the U.K.

WIRB-Copernicus Group’s clinical services division bought out trial consultancy firm Waife & Associates as it looks to boost its management services.